Toggle Main Menu Toggle Search

Open Access padlockePrints

Model-Based Risk Assessment of mAb Developability

Lookup NU author(s): Micael Karlberg, Arathi Kizhedath, Professor Jarka Glassey


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG. Monoclonal antibodies were already one of the fastest growing sectors of biopharmaceutical industry [1]. Recent research on the significant benefits of various antibodies in reducing the risks of fatality or reducing the symptoms of COVID-19, e.g., tocilizumab and sarilumab (Cortegiani et al. 2021), inevitably increases the importance of the rapid discovery of mAbs and the development of efficient manufacturing processes. Research reports frequently concentrated on the rapid discovery of new mAbs, but the developability and the manufacturability of mAbs were less explored until recently [1–4]. This chapter adopts the framework of quality by design (QbD), concentrating particularly on the model-based risk assessment of mAb developability. A case study highlights specific areas where advanced modelling approaches can contribute to speeding up the manufacturability and developability of mAbs and demonstrates the benefits and the challenges of this approach.

Publication metadata

Author(s): Karlberg M, Kizhedath A, Glassey J

Series Editor(s): Panos Pardalos, My T. Thai

Publication type: Book Chapter

Publication status: Published

Book Title: Optimization of Pharmaceutical Processes

Year: 2022

Volume: 189

Pages: 373-391

Online publication date: 07/04/2022

Acceptance date: 02/04/2018

Series Title: Springer Optimization and Its Applications

Publisher: Springer

Place Published: Switzerland


DOI: 10.1007/978-3-030-90924-6_14